Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due ...

This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle ...

Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...

Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that ...

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

This video segment explores the challenges of managing neurologic toxicities, including ICANS, in CAR-T therapy, highlighting ...

Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, highlighting strategies to address quality-of-life impacts while maintaining ...

Dr. Mohan discusses with Nurse Goff and Nurse Brigle the prevention and management of infections and neurological toxicities in patients receiving bispecific therapies, with a particular focus on the ...

The combination of tislelizumab, irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin demonstrated promising efficacy and manageable safety in gastric and GEJ cancers. Adding tislelizumab to ...

Key opinion leaders discuss strategies for managing neurotoxicity with lorlatinib and other ALK inhibitors, including monitoring adverse events and balancing symptom management with treatment efficacy ...